Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

664 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.
Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J; PARADIGMS Study Group. Chitnis T, et al. Among authors: gartner j. N Engl J Med. 2018 Sep 13;379(11):1017-1027. doi: 10.1056/NEJMoa1800149. N Engl J Med. 2018. PMID: 30207920 Free article. Clinical Trial.
Therapy of highly active pediatric multiple sclerosis.
Huppke P, Huppke B, Ellenberger D, Rostasy K, Hummel H, Stark W, Brück W, Gärtner J. Huppke P, et al. Among authors: gartner j. Mult Scler. 2019 Jan;25(1):72-80. doi: 10.1177/1352458517732843. Epub 2017 Sep 21. Mult Scler. 2019. PMID: 28933245
Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS.
Deiva K, Huppke P, Banwell B, Chitnis T, Gärtner J, Krupp L, Waubant E, Stites T, Pearce GL, Merschhemke M. Deiva K, et al. Among authors: gartner j. J Neurol Neurosurg Psychiatry. 2020 Jan;91(1):58-66. doi: 10.1136/jnnp-2019-321124. Epub 2019 Aug 29. J Neurol Neurosurg Psychiatry. 2020. PMID: 31467033 Free PMC article. Clinical Trial.
Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study.
Arnold DL, Banwell B, Bar-Or A, Ghezzi A, Greenberg BM, Waubant E, Giovannoni G, Wolinsky JS, Gärtner J, Rostásy K, Krupp L, Tardieu M, Brück W, Stites TE, Pearce GL, Häring DA, Merschhemke M, Chitnis T; PARADIGMS Study Investigators. Arnold DL, et al. Among authors: gartner j. J Neurol Neurosurg Psychiatry. 2020 May;91(5):483-492. doi: 10.1136/jnnp-2019-322138. Epub 2020 Mar 4. J Neurol Neurosurg Psychiatry. 2020. PMID: 32132224 Free PMC article. Clinical Trial.
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study.
Chitnis T, Banwell B, Krupp L, Arnold DL, Bar-Or A, Brück W, Giovannoni G, Greenberg B, Ghezzi A, Waubant E, Rostasy K, Deiva K, Huppke P, Wolinsky JS, Zhang Y, Azmon A, K-Laflamme A, Karan R, Gärtner J. Chitnis T, et al. Among authors: gartner j. Mult Scler. 2021 May;27(6):922-932. doi: 10.1177/1352458520936934. Epub 2020 Jul 7. Mult Scler. 2021. PMID: 32633694
Natalizumab use in pediatric multiple sclerosis.
Huppke P, Stark W, Zürcher C, Huppke B, Brück W, Gärtner J. Huppke P, et al. Among authors: gartner j. Arch Neurol. 2008 Dec;65(12):1655-8. doi: 10.1001/archneur.65.12.1655. Arch Neurol. 2008. PMID: 19064754
664 results